A soluble LAG-3 protein (eftilagimod alpha) and an anti-PD-L1 antibody (avelumab) tested in a phase I trial: a new combination in immuno-oncology
Al-Batran, S.-E., Mueller, D.W., Rafiyan, M.-R., Kiselicki, D., Atmaca, A., Habibzada, T., Mueller, C., Brignone, C., Triebel, F., Loose, M., Schaaf, M., Sookthai, D., Eickhoff, R., Jaeger, E., Goetze, T.O.
Published in ESMO open (01.10.2023)
Published in ESMO open (01.10.2023)
Get full text
Journal Article
Antibody‐mediated depletion of lymphocyte‐activation gene‐3 (LAG‐3+)‐activated T lymphocytes prevents delayed‐type hypersensitivity in non‐human primates
Poirier, N., Haudebourg, T., Brignone, C., Dilek, N., Hervouet, J., Minault, D., Coulon, F., de Silly, R. V., Triebel, F., Blancho, G., Vanhove, B.
Published in Clinical and experimental immunology (01.05.2011)
Published in Clinical and experimental immunology (01.05.2011)
Get full text
Journal Article
T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell–cell contacts
Demeure, C.E, Wolfers, J, Martin-Garcia, N, Gaulard, P, Triebel, F
Published in European journal of cancer (1990) (01.09.2001)
Published in European journal of cancer (1990) (01.09.2001)
Get full text
Journal Article
LAG-3, a novel lymphocyte activation gene closely related to CD4
TRIEBEL, F, JITSUKAWA, S, BAIXERAS, E, ROMAN-ROMAN, S, GENEVEE, C, VIEGAS-PEQUIGNOT, E, HERCEND, T
Published in The Journal of experimental medicine (01.05.1990)
Published in The Journal of experimental medicine (01.05.1990)
Get full text
Journal Article
Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens
BAIXERAS, E, HUARD, B, MIOSSEC, C, JITSUKAWA, S, MARTIN, M, HERCEND, T, AUFFRAY, C, TRIEBEL, F, PIATIER-TONNEAU, D
Published in The Journal of experimental medicine (01.08.1992)
Published in The Journal of experimental medicine (01.08.1992)
Get full text
Journal Article
A combination of interleukin-2 and 60 nm cationic supramolecular biovectors for the treatment of established tumours by subcutaneous or intranasal administration
El mir, S., Casanova, A., Betbeder, D., Triebel, F.
Published in European journal of cancer (1990) (01.05.2001)
Published in European journal of cancer (1990) (01.05.2001)
Get full text
Journal Article
LBA35 Primary results from TACTI-003: A randomized phase IIb trial comparing eftilagimod alpha (soluble LAG-3) plus pembrolizumab versus pembrolizumab alone in first-line recurrent or metastatic head and neck squamous cell carcinoma with CPS ≥1
Kristensen, C.A., Metcalf, R., Braña, I., Laban, S., Soria Rivas, A., Grose, D., Rubio Casadevall, J., Cheshuk, V., Dieter, S.M., Lopez Pousa, A., Kasper-Virchow, S., Doger de Spéville, B., Covela, M., Vogl, F.D., Mueller, C., Triebel, F.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
VP5-2024: Eftilagimod alpha (soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head and neck squamous cell carcinoma: Primary results from Cohort B (CPS less-than 1) of the TACTI-003 study
Metcalf, R., Laban, S., Kristensen, C.A., Ciuleanu, T-E., Braña, I., Soria Rivas, A., Dieter, S.M., Bols, A., Forster, M.D., Covela, M.R., Christian, J., Vogl, F.D., Mueller, C., Triebel, F.
Published in Annals of oncology (01.08.2024)
Published in Annals of oncology (01.08.2024)
Get full text
Journal Article
Soluble CD30 and lymphocyte activation gene-3 (CD223), as potential serological markers of T helper-type cytokine response induced by acellular pertussis vaccine
Ausiello, C M, Palazzo, R, Spensieri, F, Urbani, F, Massari, M, Triebel, F, Benagiano, M, D'Elios, M M, Del Prete, G, Cassone, A
Published in International journal of immunopathology and pharmacology (01.01.2006)
Published in International journal of immunopathology and pharmacology (01.01.2006)
Get full text
Journal Article
In vivo T-cell clonal amplification at time of acute graft-versus-host disease
Dietrich, P Y, Caignard, A, Lim, A, Chung, V, Pico, J L, Pannetier, C, Kourilsky, P, Hercend, T, Even, J, Triebel, F
Published in Blood (15.10.1994)
Published in Blood (15.10.1994)
Get full text
Journal Article
11P Results of a phase II study investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in second-line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma pts
Krebs, M.G., Majem Tarruella, M., Forster, M., Peguero, J.A., Clay, T., Felip, E., Iams, W., Roxburgh, P., Doger de Spéville, B., Bajaj, P., Mueller, C., Triebel, F.
Published in Annals of oncology (01.04.2022)
Published in Annals of oncology (01.04.2022)
Get full text
Journal Article
11MO Final data from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3) and pembrolizumab in 2nd-line metastatic NSCLC pts resistant to PD-1/PD-L1 inhibitors
Majem, M., Forster, M.D., Krebs, M.G., Peguero, J., Clay, T.D., Felip, E., Iams, W., Roxburgh, P., de Spéville, B. Doger, Bajaj, P., Mueller, C., Triebel, F.
Published in Journal of thoracic oncology (01.04.2023)
Published in Journal of thoracic oncology (01.04.2023)
Get full text
Journal Article
1266P Initial results from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected first-line metastatic non-small cell lung carcinoma
Majem, M., Felip, E., Doger, B., Akay, M., Carcereny, E., Clay, T., Krebs, M.G., Peguero, J., Triebel, F.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article